|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 3. Tcf1 and Lef1 are required for ventrolateral mesoderm
development. Vegetal view of Xpo (A-O) and XmyoD
(A'-O') expression in stage 10.5 embryos, dorsal towards the top,
injections into the right side. Xpo and XmyoD expression are
not affected by injection of 60 ng control MO (B,B') or Tcf4 MO
(C,C'), but are both significantly downregulated by injection of 60 ng
Tcf3 MO (D,D'), 20 ng Tcf1 MO (F,F') or 60 ng
Lef1 MO (K,K'). Co-injection of 0.1 ng Xbra mRNA rescues the
downregulation of both Xpo and XmyoD expression by
Tcf3 MO (E,E'), but does not rescue their downregulation caused
by Tcf1 MO (G,G') or Lef1 MO (L,L'), indicating
that while Tcf3 is required for ventrolateral mesoderm development only
because it is required for normal mesoderm induction, which is a prerequisite
for ventrolateral mesoderm development; Tcf1 and Lef1 are required for
ventrolateral mesoderm development independent of any requirement in mesoderm
induction. Downregulation of Xpo and XmyoD expression by
XlTcf1 MO or XlLef1 MO are both significantly rescued by
co-injection of either 0.3 ng XtlTcf1 mRNA (H,H'; M,M') or
HA-XlLef1 mRNA (I,I'; N,N'), but cannot be rescued by co-injection
of 0.3 ng HA-XlTcf3 mRNA (J,J'; O,O'). (P,P') Numerical
summary illustrating penetrance of effects of Tcf/Lef MOs (as labelled) or the
co-injection of these MOs with Tcf/Lef mRNAs or Xbra mRNA (as labelled),
indicating reduced or absent Xpo expression and XmyoD expression,
respectively.
|
